We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| AstraZeneca PLC | NYSE:AZN | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 54.17 | 0 | 01:00:00 |
From May 2019 to May 2024
LONDON--AstraZeneca PLC (AZN.LN) on Wednesday said it has increased its equity interest in U.S.-based biotechnology company Moderna Therapeutics with a $140 million investment.
The U.K.-listed pharmaceutical company now owns a 9% stake in Moderna after the transaction, which was made as part of Moderna's preferred-stock financing.
AstraZeneca previously acquired an equity stake in Moderna after a collaboration agreement, announced in March 2013, to develop medicines for cardiovascular, metabolic and renal diseases, as well as oncology. The companies also entered into a further collaboration agreement in January 2016 to develop and commercialize cancer medicines.
Shares of AstraZeneca at 1352 GMT were trading 0.6% lower at 5,147 pence.
Write to Tapan Panchal at tapan.panchal@wsj.com
(END) Dow Jones Newswires
August 10, 2016 10:40 ET (14:40 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
1 Year AstraZeneca Chart |
1 Month AstraZeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
